^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

A single-arm, prospective, open-label clinical study of carilizumab combined with apatinib in the treatment of non-small cell lung cancer with TP53 gene mutation

Excerpt:
...Patients with EGFR gene mutation or ALK gene rearrangement, who have received standard treatment to obtain disease progress and have TP53 gene mutation detected; 5. ...
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration

Excerpt:
Previously treated patients with advanced EGFR+/ALK+ NSCLC were enrolled and given camrelizumab 200 mg intravenously every 2 weeks plus apatinib at the recommended dose of 250 mg orally once daily…. The confirmed ORR was 18.6% (95% CI: 8.4–33.4%) and the clinical benefit response rate was 27.9% (95% CI: 15.3–43.7%).
DOI:
10.21037/tlcr-22-22
Trial ID: